Meet the Speaker: Scott Megill

The following Q&A is featured here: https://wellbeingatwork.world/meet-the-speaker-scott-megill-president-and-ceo-coriell-life-sciences/

Scott Megill is President and Chief Executive Officer of Coriell Life Sciences (CLS). With a vision to translate decades of cutting-edge genetic research into insights that empower the most precise medical care, Scott launched Coriell Life Sciences out of the renowned Coriell Institute for Medical Research in 2013. Under his leadership, CLS earned recognition as IBM’s Global Entrepreneur of the Year and has grown to become an internationally trusted provider of comprehensive medication risk management solutions, bioinformatics, and genetic interpretation and reporting services.

We are delighted to be partnering with Coriell Life Sciences for Wellbeing at Work US Summit on March 7 – 9. We caught up with Scott to find out why he is so passionate about wellbeing at work and why he is looking forward to the Summit.

1. We are thrilled that you will be speaking at our Wellbeing at Work US Summit in March. Our first and most important question is, how are you doing today?

Just fine, thank you.

2. As a leader based in the region, what are the main challenges you are facing when it comes to employee wellbeing?

There are several challenges related to employee wellbeing that we address on a regular basis: work-life balance, mental and physical health, job satisfaction, employee engagement, access to health and wellness resources, competitive health benefits, and even where the work takes place between home and office.

3. What strategies have you seen developing in the US over the past 6-12 months to address health and wellbeing in the workplace?

There’s more of a focus on consumer- or employee-driven health. We’ve seen this take place in new employee wellness programs, mental health support, flexible work arrangements, off-site and telehealth solutions, new health and safety policies, financial wellness programs, and employee engagement initiatives that focus on improving health and wellness outcomes.

4. Why is employee wellbeing so important to you personally?

Coriell Life Sciences’ success is tied directly to our team and continuously advancing our offerings. Our employees, who are also company stockholders, represent the value of our organization. It can feel like we spend more time with co-workers than with our own families, so we want to ensure our work environment is engaging, inclusive, rewarding, and enjoyable.

5. What are you most looking forward to about the Summit in March?

We look forward to hearing about the needs of various organizations that have a strong focus on employee wellness and wellbeing and the opportunity to spread the word to those employers about the availability of new genetic testing technology that could significantly benefit their populations.

6. Tell us, what is your vision for the workplace of the future, in terms of employee engagement, health and wellbeing?

Companies should be able to provide appropriate health services that support the needs of employees and dependents both short- and long-term, allowing employees to focus on the task at hand. That means data-driven decision making, personalized wellness programs, an overall culture of health and wellbeing, employee engagement programs, and flexible work arrangements where possible.

7. What areas do you think employers should be focused on over the next 12-18 months?

Employers should strongly consider incorporating genetic testing for medication safety by introducing pharmacogenomics (PGx) and comprehensive medication management (CMM). By partnering with a company, like Coriell Life Sciences, that specializes in PGx + CMM, employers can immediately understand the significant ROI and improved health outcomes potential, educate their employees on its lifetime value, and begin implementing such a program for employees and dependents that will benefit the most.

8. How has your organization been leading the way?

Coriell Life Sciences offers an ROI analysis even before signing a contract with a new organization. A risk-free, predictive population health analytics assessment provides a deep understanding of how each population can realize improved overall health outcomes, improved quality of life, reduced healthcare spending, reduced medication side effects and adverse reactions, a decrease in number and cost of outpatient visits, and a reduction in the number of emergency department visits and hospitalizations. We are industry agnostic and offer the most comprehensive pharmacogenomics + comprehensive medication management program on the market, resulting in significant economic, clinical, and humanistic outcomes for our customers.

Join us at this year’s Wellbeing at Work Summit where we’ll present, How DNA Testing Reduces Costs by Avoiding Medication Errors

Interested in learning more? Get a risk-free PGx ROI analysis for your organization today.